Kualitas bukti 4.0/5
Skor tinjauan delapan dimensi terhadap rubrik kualitas . Setiap dimensi dinilai 1–5.
- D1 Dasar sumber
- 4/5
- D2 Otoritas sumber
- 5/5
- D3 Aritmetika
- 4/5
- D4 Ketidakpastian
- 4/5
- D5 Cakupan
- 4/5
- D6 Prosa
- 4/5
- D7 Kejujuran persepsi
- 3/5
- D8 Kelengkapan peringatan
- 4/5
● faktor Anda — klik risiko ini ▾ untuk menampilkan
- Faktor Anda
≈ Sama mungkinnya dengan
Dipersepsikan
Liputan pers atas nasihat ASA 2023 dan peringatan label FDA November 2024 membingkai obat GLP-1 sebagai bahaya anestesi yang serius, dengan tajuk yang mendesak pasien untuk menghentikan Ozempic atau berisiko aspirasi selama operasi. Pembacaan intuitifnya adalah bahwa pengguna GLP-1 menghadapi peluang tinggi, hampir pasti, tersedak isi lambung yang tertinggal di meja operasi. Belum ada survei yang mengukur persepsi spesifik ini, sehingga perkiraan kasar disimpulkan dari kekhawatiran dalam liputan dan forum pasien, bukan dari jajak pendapat.
Perkiraan kasar: Framing pasien dan media menyiratkan persepsi risiko aspirasi per-prosedur pada orde beberapa persen hingga puluhan persen («jangan dibius saat memakai Ozempic»).
Sumber: intuisi redaksi, bukan hasil survei
Aktual
sekitar 1 dari 610 prosedur
Orang dewasa yang mengonsumsi agonis reseptor GLP-1 yang menjalani prosedur elektif yang memerlukan anestesi umum atau sedasi dalam
Tampilkan perhitungan
Subkelompok: orang dewasa yang menggunakan agonis reseptor GLP-1 yang menjalani satu prosedur elektif yang memerlukan anestesi umum atau sedasi dalam. Basis: PER PROSEDUR, tidak diagregasi selama seumur hidup prosedur. Perkiraan titik 0,00163 adalah tingkat aspirasi gabungan pada pengguna GLP-1 dari meta-analisis endoskopi terbesar (143/87.691 = 0,00163). Pita ketidakpastian membentang di seluruh rentang kohort dunia nyata: batas bawah (~0,0008) mendekati baseline anestesi umum populasi umum (~1 dari 8.325 = 0,00012 hingga ~1 dari 2.500 = 0,0004) dan perkiraan kohort yang lebih rendah; batas atas (~0,008) mencerminkan angka kohort bedah sebesar 0,8 % (IJS 2025). Yang penting ini adalah probabilitas aspirasi per-prosedur ABSOLUT, BUKAN kelebihan yang disebabkan GLP-1: tingkat kontrol yang dicocokkan (0,12 %-0,7 %) tumpang tindih dengan tingkat GLP-1, dan rasio odds gabungan (1,07-1,23) tidak signifikan secara statistik. Jadi angka utamanya adalah «seberapa sering pengguna GLP-1 mengalami aspirasi», yang tergolong rendah, sementara «seberapa besar obat meningkatkan risiko itu» adalah nol-hingga-belum-terbukti.
Catatan: Angka utama adalah tingkat aspirasi per-prosedur absolut untuk pengguna GLP-1 (s…
Angka utama adalah tingkat aspirasi per-prosedur absolut untuk pengguna GLP-1 (sekitar 1 dari 610 dalam meta-analisis endoskopi, hingga sekitar 1 dari 125 dalam kohort bedah yang lebih luas), BUKAN besaran yang ditambahkan obat pada risiko itu. Dua kohort dunia nyata yang besar dan meta-analisis endoskopi menemukan tingkat kontrol yang dicocokkan yang tumpang tindih dengan tingkat GLP-1, dengan rasio odds (1,07, 1,23) yang tidak signifikan secara statistik, dan kohort endoskopi TriNetX yang dicocokkan-propensitas menemukan tingkat yang secara numerik lebih rendah pada pengguna GLP-1 (hazard ratio 0,92, CI melintasi nol). Jadi kelebihan yang disebabkan obat adalah nol-hingga-belum-terbukti meskipun surogatnya (isi lambung yang tertinggal) meningkat mencolok (56 % vs 19 % pada ultrasonografi; rasio risiko 2,92 hingga 15,14). Peristiwa aspirasi jarang, sehingga perkiraan per-prosedur bertumpu pada pembilang kecil dan interval kepercayaan yang lebar; angka bedah dan endoskopi berbeda menurut jenis prosedur, urgensi, dan manajemen jalan napas. Angka ini dicakup per prosedur, bukan per seumur hidup; seseorang yang menjalani banyak prosedur mengakumulasi risiko kira-kira secara linear. Skor-mandiri 8D melewati ambang (rata-rata 4,0), dengan titik lemah utama adalah persepsi (hanya-intuisi, tanpa survei) dan penerjemahan cakupan per-prosedur-vs-seumur-hidup.
Risiko terkait
Risiko lain dengan tema serupa — untuk menjelajahi ketakutan terkait.
NAION (Ozempic)
Berapa kemungkinan kehilangan penglihatan mendadak dan permanen (NAION) akibat mengonsumsi semaglutide (Ozempic/Wegovy)?
Kafein berlebih
Berapa peluang mengalami bahaya akibat terlalu banyak minum kopi atau kafein?
Produk impor tidak aman
Berapa kemungkinan terluka oleh produk konsumen impor yang tidak aman?
Obat palsu
Berapa peluang dirugikan atau meninggal karena obat palsu atau berkualitas rendah?
Keputusan yang dipengaruhi risiko ini
Pilihan yang bergantung pada risiko ini: bagaimana pertimbangannya ditimbang.
Pilih penantang
The fear here is mechanically plausible and clinically documented at the level of the stomach. GLP-1 receptor agonists slow gastric emptying, and point-of-care ultrasound confirms the consequence: in a 2024 JAMA Surgery cohort, 56 percent of GLP-1 users had retained gastric contents before anesthesia against 19 percent of non-users, an adjusted increase of 30.5 percent. Across smaller ultrasound studies the risk ratios for retained content run from about 2.92 to 15.14. The 2023 ASA advisory, the October 2024 multisociety guidance, and a November 2024 FDA label change all responded to this, and the coverage that followed framed the drugs as a reason to fear going under.
What that machinery does not show up as is a matching surge in actual aspiration. Pulmonary aspiration under anesthesia is rare to begin with, on the order of 1 in 8,325 anesthetics in a 166,491-record baseline cohort. In GLP-1 users the measured per-procedure rate sits low: a 2025 meta-analysis of elective endoscopy found aspiration in 143 of 87,691 GLP-1 users, about 1 in 610, against 149 of 122,525 controls, with an odds ratio of 1.23 that did not reach significance. A separate surgical cohort of 392,065 patients put the figure at 0.8 percent in users versus 0.7 percent in non-users, adjusted odds ratio 1.07, no association. A propensity-matched TriNetX cohort of endoscopy patients found a numerically lower rate of aspiration pneumonitis in GLP-1 users, 0.11 percent versus 0.12 percent, hazard ratio 0.92, though the confidence interval crossed the null. The retained-content surrogate is elevated; the outcome it is supposed to predict is not, at least not measurably.
The number this entry publishes is the absolute chance that a GLP-1 user aspirates during one procedure, which is low. It is deliberately not the same as the chance the drug adds, which the cohort data leaves null or unproven. The guidance reflects that split: the 2024 multisociety statement leans toward continuing the drug for most patients and reserving extra precautions, a clear-liquid diet, an extended fast, or an ultrasound look at the stomach, for those in the dose-escalation phase, on weekly high doses, or with active nausea and bloating. Those precautions target the inflated surrogate. The aspiration events that would justify the original alarm have so far stayed close to the background rate that anesthesia carries with or without these drugs.
Fakta terkait
Aspirasi paru saat anestesi pada pengguna GLP-1 terjadi sekitar 1 dari 610 prosedur. Berita membingkai pengosongan lambung yang lambat sebagai alasan takut operasi; angka indikator pengganti ini lebih rendah daripada yang disiratkan kekhawatiran itu.
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
5/7 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
-
[1] JAMA Surgery — Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia Terverifikasi
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia- Statistik
GLP-1 RA use associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased residual gastric content; 56% (35/62) vs 19% (12/62).- Kutipan
“GLP-1 RA use was associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased RGC”
- Data sumber dari
- 2024-03-06
- Diakses
- 2026-06-13 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- This is the SURROGATE (retained gastric content), not aspiration. Raw prevalence 56% vs 19%; adjusted difference +30.5%. Increased RGC defined as solids, thick liquids, or >1.5 mL/kg clear liquids on ultrasound. Authors note they 'did not directly assess aspiration events, which are rare.' Used to establish the elevated-surrogate half of the perceived-vs-actual gap, not the headline number.
- Independensi
- University of Texas Houston cohort; independent of the endoscopy and surgery aspiration cohorts below.
-
[2] The Open Respiratory Medicine Journal — GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis Terverifikasi
GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis- Statistik
Pulmonary aspiration in 143/87,691 (0.16%) GLP-1 users vs 149/122,525 (0.12%) controls; OR 1.23 (95% CI 0.58-2.60; P=0.59), not significant.- Kutipan
“143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group had pulmonary aspiration.”
- Data sumber dari
- 2025-06-11
- Diakses
- 2026-06-13 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Source of the native counts and the normalized point estimate. 143/87,691 = 0.00163. Control rate 149/122,525 = 0.00122 overlaps, OR 1.23 not significant -> the absolute rate is low and the excess is unproven. Point estimate = 0.00163; log10 = -2.788.
- Independensi
- Pooled endoscopy meta-analysis; distinct dataset from the surgical TriNetX/IJS cohorts.
-
[3] International Journal of Surgery — Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery Terverifikasi
Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery- Statistik
Aspiration 0.8% in GLP-1 users vs 0.7% non-users (P=0.61); adjusted OR 1.07 (95% CI 0.85-1.34), no association. N=392,065 (15,745 users).- Kutipan
“After adjusting for other risk factors for aspiration, there was no association between GLP-1 agonist use and aspiration (OR = 1.07; 95% CI, 0.85–1.34).”
- Data sumber dari
- 2025-05-12
- Diakses
- 2026-06-13
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Supplies the upper end of the uncertainty band (0.8% = 0.008). Surgical population (2015-2022), broader than endoscopy, so higher absolute aspiration rate. Confirms the null excess: OR 1.07 not significant.
- Independensi
- Separate surgical cohort; conclusion converges with the endoscopy meta despite independent data.
-
[4] Journal of the Endocrine Society — Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk
Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk- Statistik
Across cohorts, aspiration ~2.6-8.3 per 1000 in GLP-1 users vs similar in non-users; retained-content risk ratios 2.92-15.14; ASA Oct 29 2024 guidance.- Kutipan
“retrospective cohort studies using large real-world evidence databases have not consistently identified a GLP-1RA-associated risk of aspiration/pneumonia for elective surgical and endoscopic procedures”
- Data sumber dari
- 2025-07-10
- Diakses
- 2026-06-13
- Perhitungan
- Review consolidating the field: per-procedure aspiration 2.61-8.32 per 1000 in users (0.0026-0.0083), bracketing the chosen band; retained-content RRs 2.92-15.14 (the elevated surrogate). Source for the multisociety guidance summary and the 'continue most patients, shared decision making' framing.
- Independensi
- Narrative review summarizing the primary cohorts above; cited for synthesis and guidance context, not as an independent dataset.
-
[5] Annals of Palliative Medicine — Perioperative pulmonary aspiration and regurgitation without aspiration in adults: a retrospective observational study of 166,491 anesthesia records Terverifikasi
Perioperative pulmonary aspiration and regurgitation without aspiration in adults: a retrospective observational study of 166,491 anesthesia records- Statistik
Perioperative aspiration in 20/166,491 anesthetics (1:8,325); morbidity 1:16,649; mortality 1:55,497.- Kutipan
“Among the 166,491 anesthesia records, 20 patients had PA (1:8,325)”
- Data sumber dari
- 2021-04-30
- Diakses
- 2026-06-13 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- General-population baseline aspiration rate under anesthesia (1:8,325 = 0.00012), pre-dating the GLP-1 era. Establishes the lower edge / reference point: GLP-1-user rates (0.0016-0.008) sit near or modestly above this baseline, consistent with the null-excess finding. Used for the lower uncertainty bound and severity context.
- Independensi
- Baseline cohort with no GLP-1 exposure measured; independent of all GLP-1 sources.
-
[6] Pharmacy Times — FDA Adds Delayed Gastric Emptying as Adverse Event on Semaglutide Label Terverifikasi
FDA Adds Delayed Gastric Emptying as Adverse Event on Semaglutide Label- Statistik
FDA added a label warning of rare postmarketing reports of pulmonary aspiration in GLP-1 users undergoing anesthesia despite reported fasting (Nov 2024).- Kutipan
“postmarking reports showing rare instances of pulmonary aspiration for patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists and undergoing elective surgeries or procedures that require general anesthesia or deep sedation”
- Data sumber dari
- 2024-11-14
- Diakses
- 2026-06-13
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- Documents the FDA regulatory action (label 'rare instances' language) that drives the public-perception half of the entry. Non-authoritative news source; used only for the FDA/labeling timeline, not for any rate.
-
[7] Endoscopy International Open — GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy
GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy- Statistik
TriNetX 1:1 propensity-matched cohort (N=46,948; 23,474 GLP-1 users vs 23,474 controls): aspiration pneumonitis 0.11% vs 0.12%, hazard ratio 0.92 (95% CI 0.54-1.56); pneumonia 0.81% vs 0.79%, hazard ratio 1.01 (95% CI 0.83-1.24). Neither difference reached significance.- Kutipan
“GLP-1 RA use before endoscopy was not associated with a higher risk of post-procedure respiratory complications compared with that in patients not prescribed GLP-1 RAs.”
- Data sumber dari
- 2025-01-13
- Diakses
- 2026-07-04 · salinan arsip
- Perhitungan
- Propensity-matched (1:1) cohort drawn from the TriNetX research network of 83 healthcare organizations. The aspiration-pneumonitis point estimate sits below 1 (HR 0.92), giving a numerically lower rate in GLP-1 users, but the confidence interval crosses the null (0.54-1.56), so this is a further null result rather than a statistically significant protective finding. Used to source and correctly qualify the "propensity-matched cohort with a lower point estimate" claim elsewhere in this entry.
- Independensi
- Separate TriNetX-derived cohort, independent of the JAMA Surgery, endoscopy meta-analysis, IJS surgical, and baseline-anesthesia sources above.








